OPUS MAGNUM AMERIS INC. OTC Expert Market

Company Information Disclosure • 公司信息披露页面

Company Overview

Legal Name
Opus Magnum Ameris Inc. (“OPUS”)
Incorporation
State of Florida, USA (Active)
Trading Symbol
OPUS OTC Expert Market
Corporate Address
Room 615, Jinyuan Building, No. 1 South Daxing Rd, Yancheng 224001, China
Telephone
+86 18101410508
Email
1484772461@qq.com
Management Location
All management and administrative functions are currently based in mainland China.
This page provides corporate and investor information consistent with U.S. OTC Markets Basic Disclosure Guidelines.

Management

Sole Director
Yaping Dai — President, CEO & CFO
Financials
Unaudited

Business Description

OPUS, formerly TeleServices Internet Group Inc., was originally a development-stage enterprise focused on evaluating and structuring business combinations. Following a share-swap transaction, OPUS now holds a group structure that includes wholly-owned subsidiaries in Hong Kong SAR and the PRC. These subsidiaries are currently not operational and are preparing to engage in medical technology, biotechnology, pharmaceutical technology, electronics, and information-technology development and consulting services.

Subsidiaries (Wholly Owned)

  • Billionaires Group Limited (Hong Kong SAR)
  • Zhongjun Times Holding Group Co., Ltd. (PR China)
  • Shanghai Xingkai Medical Technology Co., Ltd. (PR China) — established 2020; registered capital RMB 10 million (not fully paid-in); foreign trade registration; Class II Medical Device business license.

Securities Information

Common Stock
Authorized: 300,000,000 • Outstanding: 204,001,277 • Par: $0.0001 • CUSIP: 68404C102
Record Holders
589
Preferred Stock
Special 2022 Series Preferred A — Authorized: 10 • Outstanding: 10
Super Voting
Preferred A carries 60% of all shareholder votes (across all classes, including on an as‑converted basis).
Preferred A Holder
Guo Shun Tong Investment Group Limited / Cao Zhengyi

Shareholders ≥ 5% of a Class

HolderClassShares% of Class
Zhengyi CaoCommon108,000,00052.94%
Guo Shun Tong Investment Group Limited / Cao ZhengyiPreferred A1060% of total voting power
Figures per the most recent Annual Disclosure Statement and certified transfer‑agent shareholder list.

Financial Information

Fiscal Year End
December 31, 2024
Revenues
$0 (latest annual period)
Audit Status
Unaudited
Shell Status
Yes

Transfer Agent

Name
TranShare Corporation
Address
17755 North US Highway 19, Suite 140, Clearwater, FL 33764, USA
Phone
+1 303-662-1112
Email
kwhiteside@transhare.com

Investor Contact

Email
1484772461@qq.com
Telephone
+86 18101410508

Legal Notice

This page is intended to satisfy U.S. OTC Markets Basic Disclosure expectations for a non‑reporting issuer. All statements current as of the latest annual reporting period. Preferred A super‑voting description as disclosed in the annual report. Nothing herein constitutes an offer to sell or a solicitation of an offer to buy any security.

公司概况

法定名称
欧普斯玛格纳美瑞斯公司(Opus Magnum Ameris Inc.,“OPUS”)
注册地
美国佛罗里达州(状态:在存续)
交易代码
OPUS OTC Expert 市场
公司地址
中国 盐城市 大星南路1号 金源大厦 615 室(邮编:224001)
联系电话
+86 18101410508
电子邮箱
1484772461@qq.com
管理职能所在地
公司所有管理与行政职能目前均设在中国大陆。
本页面依据美国OTC市场基础信息披露指引提供公司与投资者信息。

管理层

唯一董事
戴亚萍(Yaping Dai) — 总裁、首席执行官兼首席财务官
财务报表
未经审计

业务描述

OPUS前称TeleServices Internet Group Inc.,最初作为一家开发阶段企业,专注于评估与设计并购重组。经股份互换交易后,OPUS目前持有位于香港及中国大陆的全资子公司。上述子公司目前尚未开展实质经营,正筹备进入医疗科技、生物科技、医药科技、电子与信息科技开发及咨询等业务领域。

全资子公司

  • 比里恩奈集团有限公司(香港特别行政区)
  • 中焌时代控股集团有限公司(中华人民共和国)
  • 上海杏凯医疗科技有限公司(中华人民共和国)— 成立于2020年;注册资本人民币1000万元(尚未全部实缴);具备对外贸易备案及第二类医疗器械经营备案。

证券信息

普通股
授权:300,000,000 • 流通在外:204,001,277 • 面值:$0.0001 • CUSIP:68404C102
登记股东数
589
优先股
2022年特别A系列优先股(Preferred A)— 授权:10 • 发行在外:10
超级投票权
Preferred A 享有公司全部投票权的60%(跨全部股份类别,含按转股基准)。
Preferred A 持有人
国顺通投资集团有限公司 / 曹正仪

持股比例≥5%的股东

股东股份类别股数占该类别比例
曹正仪(Zhengyi Cao)普通股108,000,00052.94%
国顺通投资集团有限公司 / 曹正仪优先股A10合计投票权的60%
数据来源:最近一期年度披露文件与过户代理人认证股东名册。

财务信息

会计年度
2024年12月31日
营业收入
0(最近年度)
审计状态
未经审计
壳公司状态

过户代理

名称
TranShare Corporation
地址
17755 North US Highway 19, Suite 140, Clearwater, FL 33764, USA
电话
+1 303-662-1112
邮箱
kwhiteside@transhare.com

投资者联系

电子邮箱
1484772461@qq.com
联系电话
+86 18101410508

法律声明

本页面旨在满足美国OTC市场对非报告型发行人的基础披露要求。所有信息以最近一个会计年度披露为准。优先股A之超级投票安排以年度报告所披露为依据。本页面不构成任何证券之出售要约或购置邀请。